| ［1］ |
Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA［J］. J Drugs Dermatol, 2012,11（12）:e76⁃e79.
|
| ［2］ |
张二佳, 林彤. A型肉毒毒素微滴注射治疗玫瑰痤疮的研究进展［J］. 中国麻风皮肤病杂志, 2021,37（9）:610⁃613. doi: 10.12144/zgmfskin202109610.
|
| ［3］ |
曾黛琳, 于波, 吴琳. 肉毒毒素微滴注射治疗玫瑰痤疮的研究进展［J］. 实用皮肤病学杂志, 2021,14（5）:297⁃300. doi: 10.11786/sypfbxzz.1674⁃1293.20210510.
|
| ［4］ |
Bloom BS, Payongayong L, Mourin A, et al. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea［J］. Dermatol Surg, 2015,41 Suppl 1:S9⁃16. doi: 10.1097/DSS. 0000000000000277.
|
| ［5］ |
Kim MJ, Kim JH, Cheon HI, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double⁃blind, placebo⁃controlled, split⁃face pilot study in rosacea patients with facial erythema［J］. Dermatol Surg, 2019,45（9）:1155⁃1162. doi: 10. 1097/DSS.0000000000001819.
|
| ［6］ |
Sundaram H, Signorini M, Liew S, et al. Global aesthetics consensus: botulinum toxin type a⁃⁃evidence⁃based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications［J］. Plast Reconstr Surg, 2016,137（3）:518e⁃529e. doi: 10.1097/01.prs. 0000475758.63709.23.
|
| ［7］ |
中华医学会整形外科学分会微创美容专业学组. A型肉毒毒素用于面部医学美容的临床专家共识［J］. 中华整形外科杂志, 2018,34（10）:791⁃795,802. doi: 10.3760/cma.j.issn.1009⁃4598.2018.10.001.
|
| ［8］ |
中国医师协会皮肤科医师分会注射美容亚专业委员会. 肉毒毒素注射在皮肤美容中应用的专家共识［J］. 中国美容医学, 2017,26（8）:3⁃8.
|
| ［9］ |
肉毒毒素治疗应用专家组, 中华医学会神经病学分会帕金森病及运动障碍学组. 中国肉毒毒素治疗应用专家共识［J］. 中华神经科杂志, 2018,51（10）:779⁃786. doi: 10.3760/cma.j.issn.1006⁃7876.2018.10.002.
|
| ［10］ |
Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee［J］. J Am Acad Dermatol, 2018,78（1）:148⁃155. doi: 10.1016/j.jaad.2017.08.037.
|
| ［11］ |
Thiboutot D, Anderson R, Cook⁃Bolden F, et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee［J］. J Am Acad Dermatol, 2020,82（6）:1501⁃1510. doi: 10.1016/j.jaad.2020.01. 077.
|
| ［12］ |
中华医学会皮肤性病学分会玫瑰痤疮研究中心, 中国医师协会皮肤科医师分会玫瑰痤疮专业委员会. 中国玫瑰痤疮诊疗指南（2021版）［J］. 中华皮肤科杂志, 2021,54（4）:279⁃288. doi: 10.35541/cjd.20201078.
|
| ［13］ |
汪犇, 赵志祥, 简丹, 等. 中国玫瑰痤疮临床特征分析和诊断标准再探讨［J］. 中华皮肤科杂志, 2020,53（9）:675⁃679. doi: 10.35541/cjd.20200376.
|
| ［14］ |
Schaller M, Dirschka T, Lonne⁃Rahm SB, et al. The importance of assessing burning and stinging when managing rosacea: a review［J］. Acta Derm Venereol, 2021,101（10）:adv00584. doi: 10.2340/actadv.v101.356.
|
| ［15］ |
Tan J, Steinhoff M, Bewley A, et al. Characterizing high⁃burden rosacea subjects: a multivariate risk factor analysis from a global survey［J］. J Dermatolog Treat, 2020,31（2）:168⁃174. doi: 10. 1080/09546634.2019.1623368.
|
| ［16］ |
Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea［J］. J Investig Dermatol Symp Proc, 2011,15（1）:53⁃62. doi: 10.1038/jidsymp.2011.6.
|
| ［17］ |
Drummond PD, Su D. Endothelial and axon reflex vasodilatation to acetylcholine in rosacea⁃affected skin［J］. Arch Dermatol Res, 2012,304（2）:133⁃137. doi: 10.1007/s00403⁃011⁃1177⁃1.
|
| ［18］ |
Báez A, Paleari J, Durán MN, et al. Frey syndrome secondary to submaxillectomy and botulinic treatment［J］. Medicina （B Aires）, 2007,67（5）:478⁃480.
|
| ［19］ |
Khan TT, Herne K, Dayan SH, et al. Facial blanching due to neurotoxins: proposed mechanisms［J］. Dermatol Surg, 2013,39（1 Pt 1）:24⁃29. doi: 10.1111/dsu.12057.
|
| ［20］ |
Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea［J］. F1000Res, 2018,7:1885. doi: 10. 12688/f1000research.16537.1.
|
| ［21］ |
Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action［J］. Arq Neuropsiquiatr, 2005,63（1）:180⁃185. doi: 10.1590/s0004⁃282x2005000100035.
|
| ［22］ |
Choi JE, Di Nardo A. Skin neurogenic inflammation［J］. Semin Immunopathol, 2018,40（3）:249⁃259. doi: 10.1007/s00281⁃018⁃0675⁃z.
|
| ［23］ |
Kellogg DL Jr, Zhao JL, Wu Y, et al. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans［J］. J Appl Physiol （1985）, 2012,113（10）:1512⁃1518. doi: 10.1152/japplphysiol.00859.2012.
|
| ［24］ |
Mascarenhas NL, Wang Z, Chang YL, et al. TRPV4 mediates mast cell activation in cathelicidin⁃induced rosacea inflammation［J］. J Invest Dermatol, 2017,137（4）:972⁃975. doi: 10.1016/j.jid.2016.10.046.
|
| ［25］ |
Wang L, Wang YJ, Hao D, et al. The theranostics role of mast cells in the pathophysiology of rosacea［J］. Front Med （Lausanne）, 2019,6:324. doi: 10.3389/fmed.2019.00324.
|
| ［26］ |
Choi JE, Werbel T, Wang Z, et al. Botulinum toxin blocks mast cells and prevents rosacea like inflammation［J］. J Dermatol Sci, 2019,93（1）:58⁃64. doi: 10.1016/j.jdermsci.2018.12.004.
|
| ［27］ |
Pickett A. Can botulinum toxin cause anaphylaxis after an aesthetic treatment?［J］. Clin Exp Dermatol, 2018,43（5）:599⁃600. doi: 10.1111/ced.13342.
|
| ［28］ |
Gheisari M, Moslemi Haghighi S, Baghani M, et al. Generalized drug eruption with vasculopathic reaction pattern to botulinum toxin injection［J］. Dermatol Ther, 2020,33（6）:e14294. doi: 10.1111/dth.14294.
|
| ［29］ |
Grassegger A. Comment on Tamura et al′s Allergic reaction to botulinum toxin: positive intradermal test［J］. Dermatol Surg, 2009,35（6）:1015. doi: 10.1111/j.1524⁃4725.2009.01176.x.
|
| ［30］ |
Cohen JL, Scuderi N. Safety and Patient Satisfaction of AbobotulinumtoxinA for aesthetic use: a systematic review［J］. Aesthet Surg J, 2017,37（suppl_1）:S32⁃S44. doi: 10.1093/asj/sjx010.
|
| ［31］ |
Wu W. Microbotox of the lower face and neck: evolution of a personal technique and its clinical effects［J］. Plast Reconstr Surg, 2015,136（5 Suppl）:92S⁃100S. doi: 10.1097/PRS.000000 0000001827.
|
| ［32］ |
Chen Y, Hua W, Li A, et al. Analysis of facial redness by comparing VISIA（®） from Canfield and CSKIN（®） from Yanyun Technology［J］. Skin Res Technol, 2020,26（5）:696⁃701. doi: 10.1111/srt.12856.
|
| ［33］ |
Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long⁃lasting results［J］. Br J Dermatol, 2008,159（3）:628⁃632. doi: 10.1111/j.1365⁃2133.2008.08702.x.
|
| ［34］ |
Carruthers J, Carruthers A. The effect of full⁃face broadband light treatments alone and in combination with bilateral crow′s feet Botulinum toxin type A chemodenervation［J］. Dermatol Surg, 2004,30（3）:355⁃366. doi: 10.1111/j.1524⁃4725.2004. 30101.x.
|
| ［35］ |
Khoury JG, Saluja R, Goldman MP. The effect of botulinum toxin type A on full⁃face intense pulsed light treatment: a randomized, double⁃blind, split⁃face study［J］. Dermatol Surg, 2008,34（8）:1062⁃1069. doi: 10.1111/j.1524⁃4725.2008.34207.x.
|
| ［36］ |
Al⁃Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type⁃A in the treatment of rosacea⁃associated erythema and flushing［J］. Dermatol Ther, 2020,33（6）:e13976. doi: 10.1111/dth.13976.
|
| ［37］ |
Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1775⁃1791. doi: 10.1111/jdv.14349.
|
